# NIH Reporter #5I01CX002060-05

Immunogenicity of recombinant zoster vaccine in Rheumatoid arthritis patients

**Recipient:** LOUIS STOKES CLEVELAND VA MEDICAL CENTER

**Awarded:** September 18, 2026

**Identifier:** 5I01CX002060-05

This award supports research on the immune response to the recombinant zoster vaccine in RA patients, particularly the impact of DMARD therapies on vaccine effectiveness and safety.

### Description

The study focuses on the immunogenicity of the recombinant zoster vaccine (RZV) in Rheumatoid arthritis (RA) patients, examining the effects of disease-modifying antirheumatic drugs (DMARDs) on vaccine response. It aims to determine the differential effects of synthetic and biologic DMARD therapies on vaccine immunogenicity, explore mechanistic pathways using systems biology, and compare adverse event profiles between RA patients and controls.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11333512)